

Radiation Dose Response of Renal Parenchyma Assessed by CT Contrast Enhancement Change Following Kidney Stereotactic Body Radiotherapy

Liyuan Chen, PhD¹; Young Suk Kwon, MD¹; Philip Taboada, MD¹; Raquibul Hannan, MD, PhD¹; Jing Wang, PhD¹
¹ Department of Radiation Oncology, University of Texas Southwestern Medical Center

INTRODUCTION

Rationale/Impact: Preservation of renal function is critical in kidney Stereotactic Body Radiotherapy (SBRT). While clinical constraints typically rely on whole-organ dose metrics (e.g., mean dose), radiation nephrotoxicity is a local phenomenon involving complex parenchymal tissue changes that lead to functional decline.

- **Imaging surrogate:** Kidney parenchymal radiodensity (Hounsfield Units) on portal venous CT reflects iodine accumulation, a function of local perfusion and glomerular filtration.
- **Hypothesis:** The paired pre- and post-treatment contrast-enhanced CT scans can be analyzed, to quantify renal parenchyma functional changes in response to radiation dose for patients treated with kidney SBRT. Radiation-induced injury manifests as a measurable, dose-dependent reduction in local parenchymal contrast enhancement (Δ HU), potentially suggesting new dosimetric objectives for kidney functional sparing.

RESULTS & DISCUSSION

Key findings:

- **Dose Response:** Both cohorts demonstrate a non-linear response where the reduction in enhancement appears to stabilize at high doses.
 - 36 Gy Cohort: Mean Δ HU decreased from approximately -7 HU in low-dose regions (<10 Gy) to approximately -16 HU at 22.5 Gy, with diminishing incremental change beyond this level (see Figure 1).
 - 40 Gy Cohort: Mean Δ HU remained near approximately -7 HU in low-dose regions (<15 Gy), then dropped sharply to approximately -20 HU at 26.5 Gy before plateauing (see Figure 2).
- Similar trends persisted in kidney-minus-PTV analyses, suggesting collateral parenchymal injury rather than tumor necrosis alone.

Interpretation and Future work: The observed "saturation" suggests that once a voxel exceeds a certain dose (approx. 22–26 Gy), local tissue function is maximally compromised.

- **Potential Planning Implication:** The observed non-linear dose–response suggests that limiting the volume of kidney receiving doses within the intermediate dose range (associated with the sharpest change in contrast enhancement) may be more relevant for kidney-sparing radiotherapy planning than focusing solely on high-dose regions where injury appears to saturate.
- **Future work:** These results are preliminary and limited by the small sample size (N=12). Validation against standard functional renal scans with expanded patient cohort is currently under way, and more comprehensive results will be presented at the APPM annual meeting.

METHODS AND MATERIALS

We developed a pipeline to quantify local changes while mitigating technical variability:

- **Study cohort:** Twelve kidney SBRT patients were retrospectively analyzed in two prescription cohorts: 36 Gy / 3 fractions (n=6) and 40 Gy / 5 fractions (n=6).
- **Image processing:** Pre- and post-treatment portal venous phase CT scans were deformably registered. Post-treatment CT was normalized slice-by-slice to align mean abdominal aorta HU with the pre-treatment CT.
- **Parenchyma extraction:** Renal parenchyma was segmented on pre-treatment CT using a 20-200 HU density gate to exclude cysts and collecting systems.
- **Voxel analysis:** Voxel-wise enhancement change (Δ HU = Post - Pre) was summarized in 3-Gy dose-bin intervals to generate population-level dose-response curves.




Figure 3: An example of the 3D view of the subtracted image overlaying with prior SBRT CT (a) and Dose (b).

CONCLUSIONS

Voxel-wise paired CT analysis demonstrates a dose-dependent reduction in renal parenchymal contrast enhancement following kidney SBRT. The non-linear dose-response suggests that limiting kidney volume receiving intermediate-dose ranges associated with the sharpest enhancement decline may be more relevant for kidney-sparing radiotherapy planning than focusing only on high-dose regions where injury saturates. However, this preliminary retrospective analysis is limited by small sample size (N=12). Validation against standard functional renal scans and expanded cohort analysis is underway.




Figure 1: Mean HU change (left) and %HU change (right) for the 36 Gy/3fx cohort, showing a progressive decline that begins to stabilize at high doses.




Figure 2: Mean HU change (left) and %HU change (right) for the 40 Gy/5fx cohort. A steep dose-dependent reduction is observed, flattening beyond 26 Gy.